Printer Friendly

IVAX COMMENCES DISTRIBUTION OF VERAPAMIL

 IVAX COMMENCES DISTRIBUTION OF VERAPAMIL
 MIAMI, Aug. 19 /PRNewswire/ -- IVAX Corporation (AMEX: IVX)


announced today that its wholly owned subsidiary, Baker Norton Pharmaceuticals, Inc., has begun shipment of 240 mg. verapamil HCI ER tablets. The product is being marketed by Goldline Laboratories, Inc., a wholly owned subsidiary of IVAX.
 Verapamil HCI ER, which is a sustained release product administered once per day for the treatment of hypertension, is a generic equivalent of the products marketed by G.D. Searle & Co. under the brand name Calan(R) SR and by Knoll Pharmaceuticals under the brand name Isoptin(R) SR. Baker Norton Pharmaceuticals received approval from the United States Food and Drug Administration of its Abbreviated New Drug Application for 240 mg. verapamil HCI ER on July 31, 1992. Calan(R) is a registered trademark of G.D. Searle & Co., and Isoptin(R) SR is a registered trademark of Knoll Pharmaceuticals.
 IVAX Corporation is a holding company with subsidiaries involved in specialty chemicals, pharmaceuticals and medical diagnostics. IVAX' principal subsidiaries include Baker Norton Pharmaceuticals, Inc., a developer and marketer of unique brand name pharmaceuticals; Norton Healthcare Limited, a leading manufacturer and marketer of off-patent pharmaceuticals in the United Kingdom, Ireland and other countries; Goldline Laboratories, Inc., a national marketer of off-patent prescription and over the counter pharmaceuticals in the United States; Baker Cummins Dermatologicals, Inc., a dermatological products company; Flori Roberts, Inc., a skin care and cosmetics company; DVM Pharmaceuticals Inc., a veterinary products company; Diamedix Corporation, a medical diagnostics company; Delta Biologicals S.r.l., a marketer of medical diagnostic tests and instruments in Italy; and IVAX Industries, Inc., a chemical specialties business.
 -0- 8/19/92
 /CONTACT: Richard C. Pfenniger Jr., senior vice president-legal affairs of IVAX Corporation, 305-590-2309/
 (IVX) CO: IVAX Corporation ST: Florida IN: MTC SU:


AW-SS -- FL001 -- 1173 08/19/92 07:00 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 19, 1992
Words:307
Previous Article:CELEBRITY NOMINEES TO APPEAR AT PRIMETIME EMMYS RECEPTION, AUG. 25
Next Article:C-COR ANNOUNCES 1992 YEAR-END FINANCIAL RESULTS, REVENUES UP 59 PERCENT
Topics:


Related Articles
IVAX CORPORATION ANNOUNCES THE APPROVAL OF ITS ABBREVIATED NEW DRUG APPLICATION FOR VERAPAMIL
IVAX CORPORATION ANNOUNCES THE APPROVAL OF ITS ABBREVIATED NEW DRUG APPLICATION FOR VERAPAMIL
IVAX AGREES TO CEASE SALE OF LOOK-ALIKE GENERIC
IVAX CONTINUES TO MANUFACTURE AND DISTRIBUTE VERAPAMIL
NEW JERSEY STATE FORMULARY APPROVES BAKER NORTON'S GENERIC VERAPAMIL
IVAX AND KNOLL ANNOUNCED SETTLEMENT OF VERAPAMIL LITIGATION
IVAX CORPORATION ANNOUNCES THE APPROVAL OF ITS ABBREVIATED NEW DRUG APPLICATION FOR 180 MG. VERAPAMIL TABLETS
IVAX ANNOUNCES SETTLEMENT OF VERAPAMIL LITIGATION
IVAX SUBSIDIARY COMMENCES DISTRIBUTION OF VERAPAMIL
IVAX CORPORATION AND ZENITH LABORATORIES, INC. ANNOUNCE COMPLIANCE WITH FTC REQUEST

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters